Colin MacKay, CEO at Symbiosis Pharmaceutical Services.
Symbiosis Pharmaceutical Services have revealed a new freeze drying (lyophilisation) service to assist with the manufacture of bulk intermediates and APIs.
The Scotland-based company have always provided lyophilisation for the sterile filling of vials but this expansion means the manufacturer is now able to offer both aseptic and low bioburden clean room dispensing of bulk materials.
The contract manufacturing organisation revealed its plans after winning several new contracts and is supporting clients in the US, Europe and Asia.
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: “This service launch has very much been driven by market demand from biotech and pharmaceutical companies requiring either a one-off batch or the ongoing bulk lyophilisation of API or finished product.
“Our state-of-the-art facilities, licenses and technical capabilities enable us to offer such a service to the market in a reliable and responsive manner, helping meet clients’ product supply needs in a timely fashion.”
Symbiosis specialises in sterile injectables and the aseptic manufacturing of drug products into vials. Its core manufacturing capability takes place within a purpose-built facility, designed for the manufacture of sterile drug products.
“For us, it’s all about adding as much value to clients’ projects as possible in terms of expertise where they need it, while ensuring every batch is produced under stringent compliance and with quality assurance release,” added Colin.
“Like every service at Symbiosis, the core is regulatory-compliant and time-focused contract sterile fill/finish.”